Nanobiotix Announces Promising Data on NBTXR3 for Head and Neck Cancer Patients

Nanobiotix has revealed new data from Study 1100 indicating strong disease control and tumor response in 68 heavily pre-treated patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). Patients received RT-activated NBTXR3 followed by anti-PD-1 treatment. This data was presented at the 2024 Annual Meeting of the American Society for Clinical Oncology (ASCO).

Among the anti-PD-1 naïve patients, there was a 48% overall response rate (ORR) and a 76% disease control rate (DCR). For the anti-PD-1 resistant group, the ORR was 28% and the DCR was 68%. Moreover, the anti-PD-1 naïve patients showed a median progression-free survival (mPFS) of 7.3 months and a median overall survival (mOS) of 26.2 months.

The study also reported a favorable safety profile for the combined treatment. Serious adverse events related to the therapy occurred in only 8.8% of the patients. These promising preliminary results call for further investigation through randomized clinical trials.